- Home
- MKTX vs HALO Comparison
MKTX vs HALO Comparison
Compare MKTX & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKTX | HALO |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.4B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | MKTX | HALO |
|---|---|---|
| Price | $182.12 | $67.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $211.30 | $73.33 |
| AVG Volume (30 Days) | 718.3K | ★ 2.2M |
| Earning Date | 02-05-2026 | 02-17-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | ★ 5.87 | 4.74 |
| Revenue | $839,263,000.00 | ★ $1,242,852,000.00 |
| Revenue This Year | $6.33 | $34.83 |
| Revenue Next Year | $8.10 | $24.84 |
| P/E Ratio | $31.08 | ★ $14.29 |
| Revenue Growth | 3.37 | ★ 31.19 |
| 52 Week Low | $156.17 | $47.50 |
| 52 Week High | $232.84 | $79.50 |
Technical Indicators
Market Signals| Indicator | MKTX | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 60.95 | 51.98 |
| Support Level | $181.22 | $67.95 |
| Resistance Level | $184.39 | $69.48 |
| Average True Range (ATR) | 2.62 | 1.59 |
| MACD | 0.25 | 0.47 |
| Stochastic Oscillator | 68.52 | 74.62 |
Price Performance
Historical ComparisonAbout MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.